The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients

Immunol Rev. 2023 Sep;318(1):4-10. doi: 10.1111/imr.13270. Epub 2023 Aug 26.

Author

Alexandra-Chloé Villani^{1

2

3

4}

Affiliations

¹ Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Massachusetts, Boston, USA.
² Mass General Cancer Center, Center for Cancer Research, Massachusetts General Hospital, Massachusetts, Boston, USA.
³ Broad Institute of Massachusetts Institute of Technology and Harvard, Massachusetts, Cambridge, USA.
⁴ Harvard Medical School, Massachusetts, Boston, USA.

PMID: 37632320
DOI: 10.1111/imr.13270

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

CTLA-4 Antigen
Humans
Immunotherapy / adverse effects
Neoplasms*

Substances

CTLA-4 Antigen

Grants and funding

DP2 CA247831/CA/NCI NIH HHS/United States